Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Apertura Gene Therapy
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apertura Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners
Details : Galibra Neuroscience and Emugen Therapeutics will utilize Apertura's human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Apertura Gene Therapy
Deal Size : Undisclosed
Deal Type : Licensing Agreement